Patent ID: 7081250

Claim:
A method of treating with oxybutynin a human subject having overactive bladder, while minimizing an anticholinergic or antimuscarinic adverse drug experience associated with said oxybutynin treatment therapy comprising the step of: administering as a transdermal patch, a composition comprising oxybutynin to said subject to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5:1 to about 5:1, wherein the metabolite of oxybutynin is N-desethyloxybutynin, and wherein the transdermal patch includes an effective amount of a permeation enhancer selected from the group consisting essentially of: fatty acids, fatty acid esters, fatty alcohols, fatty acid esters of lactic acid or glycolic acid, glycerol di-and monoesters, short chain alcohols, and mixtures thereof.